|
[1]
|
McEntee, M.F., Ziegler, C., Reel, D., et al. (2008) Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-independent prostate cancer. American Journal of Pathology, 173, 256-268.
http://dx.doi.org/10.2353/ajpath.2008.070989
|
|
[2]
|
Chu, G.C., Dunn, N.R., Anderson, D.C., et al. (2004) Differential requirements for Smad4 in TGFB-dependent patterning of the early mouse embryo. Development, 131, 3501-3512. http://dx.doi.org/10.1242/dev.01248
|
|
[3]
|
Fields, S.Z., et al. (2013) Activin receptor antagonists for cancer-related anaemia and bone disease. Expert Opinion on Investigational Drugs, 22, 87-101.
http://dx.doi.org/10.1517/13543784.2013.738666
|
|
[4]
|
Levy, L. and Hill, C.S. (2005) Smad4 dependency defines two classes of transforming growth factor B (TGF-B) target genes and distinguishes TGF-B induced epithelialmesenchymal transition from its antiproliferative and migratory responses. Molecular and Cellular Biology, 25, 8108-8125.
http://dx.doi.org/10.1128/MCB.25.18.8108-8125.2005
|
|
[5]
|
Attisano, L. and Wrana, J.L. (2002) Signal Transduction by the TGF-B superfamily. Science, 296, 1646-1647.
http://dx.doi.org/10.1126/science.1071809
|
|
[6]
|
Heldin, C.H., Miyazono, K. and Dijke, P.T. (1997) TGFB signalling from cell membrane to nucleus through SMAD proteins. Nature, 390, 465-471.
http://dx.doi.org/10.1038/37284
|
|
[7]
|
Derynck, R. and Zheng, Y.E. (2003) Smad-dependent and Smad-independent pathways in TGFB family signalling. Nature, 425, 577-584.
http://dx.doi.org/10.1038/nature02006
|
|
[8]
|
Ramel, M.C. and Hill, C.S. (2012) Spatial regulation of BMP activity. FEBS Letters, 586, 1929-1941.
http://dx.doi.org/10.1016/j.febslet.2012.02.035
|
|
[9]
|
Mesnard, D., Guzman-Ayala, M. and Constam, D.B. (2006) Nodal specifies embryonic visceral endoderm and sustains pluripotent cells in the epiblast before overt axial patterning. Development, 133, 2497-2505.
|
|
[10]
|
Ogawa, K., et al. (2007) Activin-Nodal signalling is involved in propagation of mouse embryonic stem cells. Journal of Cell Science, 120, 55-65.
http://dx.doi.org/10.1242/jcs.03296
|
|
[11]
|
Wu, Z., et al. (2008) Combinatorial signals of activin/nodal and bone morphogenic protein regulate the early lineage segregation of human embryonic stem cells. The Journal of Biological Chemistry, 283, 24991-25002.
http://dx.doi.org/10.1074/jbc.M803893200
|
|
[12]
|
Topczewska, J.M., et al. (2006) Embryonic and tumorigenic pathways converge via nodal signalling: Role in melanoma aggressiveness. Nature Medicine, 12, 925-932.
http://dx.doi.org/10.1038/nm1448
|
|
[13]
|
Bujis, J.T., et al. (2007) BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in Vivo. American Journal of Pathology, 171, 1047-1057.
http://dx.doi.org/10.2353/ajpath.2007.070168
|
|
[14]
|
Kingsley, D.M. (1994) The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes & Development, 8, 133-146. http://dx.doi.org/10.1101/gad.8.2.133
|
|
[15]
|
Massague, J. and Gomis, R.R. (2006) The logic of TGFB signalling. FEBS Letters, 12, 2811-2820.
http://dx.doi.org/10.1016/j.febslet.2006.04.033
|
|
[16]
|
Katusno, Y., et al. (2008) Bone morphogenetic protein signalling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene, 27, 6322-6333. http://dx.doi.org/10.1038/onc.2008.232
|
|
[17]
|
Kang, H.Y., et al. (2001) From transforming growth factor-B signalling to androgen action: Identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. PNAS, 90, 3018-3023.
http://dx.doi.org/10.1073/pnas.061305498
|
|
[18]
|
Iyer, S., et al. (2005) Targeting TGF-B Signaling for Cancer Therapy. Cancer Biology & Therapy, 4, 261-266.
http://dx.doi.org/10.4161/cbt.4.3.1566
|
|
[19]
|
Schlingensiepen, K.H., et al. (2004) The TGFbeta1 antisense oligonucleotide AP 11014 for treatment of nonsmall cell lung colorectal and prostate cancers: Preclinical studies. Journal of Clinical Oncology, 22, 31-32.
|
|
[20]
|
Seth, P., et al. (2006) Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor B receptor II and human immunoglobulin Fc for breast cancer therapy. Human Gene Therapy, 17, 1152-1160.
http://dx.doi.org/10.1089/hum.2006.17.1152
|
|
[21]
|
Thalmann, G.N., et al. (2000) LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate, 44, 91-103.
http://dx.doi.org/10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L
|
|
[22]
|
Lasaro, M.O. and Ertl, H.C. (2009) New insights on adenovirus as vaccine vectors. Molecular Therapy, 17, 1333-1339. http://dx.doi.org/10.1038/mt.2009.130
|
|
[23]
|
Khare, R., et al. (2011) Advances and future challenges in adenoviral vector pharmacology and targeting. Current Gene Therapy, 11, 241-258.
http://dx.doi.org/10.2174/156652311796150363
|
|
[24]
|
Hu, Z., et al. (2012) Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-b inhibits established bone metastasis in a prostate cancer mouse model. Human Gene Therapy, 23, 1-12.
http://dx.doi.org/10.1089/hum.2012.040
|
|
[25]
|
Oh, S., et al. (2013) Transforming growth factor-B gene silencing using adenovirus expressing using adenovirus expressing TGF-B1 or TGF-B2 shRNA. Cancer Gene Therapy, 20, 94-100.
http://dx.doi.org/10.1038/cgt.2012.90
|
|
[26]
|
Freytag, S.O., et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Research, 63, 7497-7506.
|
|
[27]
|
Lubaroff, D.M., et al. (2006) Clinical protocol: Phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer. Human Gene Therapy, 17, 220-229.
|
|
[28]
|
Shobana, R., et al. (2013) Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. Journal of Virology, 87, 3792-3800.
http://dx.doi.org/10.1038/cgt.2012.90
|
|
[29]
|
Sun, A., et al. (2009) Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumour eradication of prostate cancer xenografts in nude mice: A preclinical study. Cancer Therapy, 126, 764-774.
|
|
[30]
|
Pan, J.G., et al. (2012) The adeno-associated virus-mediated HSV-TK/GCV suicide system: A potential strategy for the treatment of bladder carcinoma. Medical Oncology, 29, 1938-1947.
http://dx.doi.org/10.1007/s12032-011-0091-x
|
|
[31]
|
Eertwegh, A.J.M., et al. (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial. Lancet Oncology, 13, 509-517.
http://dx.doi.org/10.1016/S1470-2045(12)70007-4
|
|
[32]
|
Manno, C.S., et al. (2003) AAV-mediated factor IX gene transfer in skeletal muscle in patients with severe haemophilia B. Blood, 101, 2963-2972.
http://dx.doi.org/10.1182/blood-2002-10-3296
|
|
[33]
|
Manno, C.S., et al. (2006) Successful transduction of liver in haemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine, 12, 342-347. http://dx.doi.org/10.1038/nm1358
|